


ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



ASX Release

22 January 2026

APPOINTMENT OF COMPANY SECRETARY AND CFO

MELBOURNE, AUSTRALIA 22 January 2026: Arovella Therapeutics Ltd (ASX: ALA) is pleased to announce the appointment of Mr Lachie Mallia as Company Secretary and Chief Financial Officer (CFO) of Arovella effective 22 January 2026. Lachie replaces fellow Bio101 Financial Advisory (Bio101) Director Mr Tim Luscombe, who has held those positions since 1 December 2023.

Lachie is a Director at Bio101, a financial services firm providing outsourced CFO, taxation, company secretarial and transaction advisory services to the Healthcare sector. Lachie brings extensive finance and commercial expertise, having worked with both public and private companies across Australia for several years. He currently serves as a CFO and Company Secretary for a number of private Healthcare companies. Lachie holds a Bachelor of Business and Bachelor of Banking and Finance from Monash University and a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

Mr Mallia is responsible for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

Release authorised by the Arovella Therapeutics Limited Board of Directors.

Dr Michael Baker

Chief Executive Officer & Managing Director

Arovella Therapeutics Ltd

Tel +61 (0) 403 468 187

investor@arovella.com

NOTES TO EDITORS:**About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.